AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial

AstraZeneca's oral relaxin drug AZD5462 hits its HFpEF endpoint but narrowly misses in HFrEF in the Phase 2b LUMINARA heart failure trial.

Raccontata daendpoints.news